The ProShare Advisors LLC Sells 1,413 Shares of Cambrex Co. (CBM)

The ProShare Advisors LLC Sells 1,413 Shares of Cambrex Co. (CBM)

Other large investors have also recently added to or reduced their stakes in the company. Congress Asset Management Co. MA bought a new stake in shares of Cambrex during the fourth quarter worth about $57,572,000. Norges Bank bought a new stake in shares of Cambrex during the fourth quarter worth about $16,903,000. Russell Investments Group Ltd. bought a new stake in shares of Cambrex during the fourth quarter worth about $14,500,000. FMR LLC boosted its stake in shares of Cambrex by 44.7% in the fourth quarter. FMR LLC now owns 504,448 shares of the biotechnology company’s stock worth $27,214,000 after buying an additional 155,753 shares in the last quarter. Finally, Columbia Wanger Asset Management LLC boosted its stake in shares of Cambrex by 41.4% in the fourth quarter. Columbia Wanger Asset Management LLC now owns 269,795 shares of the biotechnology company’s stock worth $14,555,000 after buying an additional 79,009 shares in the last quarter. Hedge funds and other institutional investors own 98.23% of the company’s stock.

ProShare Advisors LLC reduced its stake in shares of Cambrex Co. (NYSE:CBM) by 24.2% during the first quarter, according to its most recent filing with the SEC. The firm owned 4,420 shares of the biotechnology company’s stock after selling 1,413 shares during the period. ProShare Advisors LLC’s holdings in Cambrex were worth $243,000 at the end of the most recent quarter.

Shares of Cambrex Co. (CBM) opened at 55.90 on Monday. The company has a market capitalization of $1.82 billion, a P/E ratio of 21.28 and a beta of 1.95. Cambrex Co. has a 12 month low of $38.30 and a 12 month high of $62.95. The company’s 50 day moving average price is $54.91 and its 200 day moving average price is $53.64.

Cambrex (NYSE:CBM) last announced its quarterly earnings results on Thursday, May 4th. The biotechnology company reported $0.68 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.51 by $0.17. Cambrex had a return on equity of 24.53% and a net margin of 16.65%. The company had revenue of $105.01 million during the quarter, compared to analysts’ expectations of $99.05 million. During the same period in the previous year, the business earned $0.50 earnings per share. The firm’s quarterly revenue was up 10.9% compared to the same quarter last year. Analysts expect that Cambrex Co. will post $3.02 EPS for the current fiscal year.

A number of equities research analysts have recently issued reports on CBM shares. Zacks Investment Research upgraded Cambrex from a “hold” rating to a “buy” rating and set a $59.00 price objective on the stock in a research note on Thursday, May 11th. ValuEngine cut Cambrex from a “buy” rating to a “hold” rating in a research note on Friday. Stephens set a $61.00 price objective on Cambrex and gave the stock a “buy” rating in a research note on Monday, February 6th. Finally, Craig Hallum set a $70.00 price objective on Cambrex and gave the stock a “buy” rating in a research note on Monday, February 6th. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. The company has an average rating of “Buy” and a consensus price target of $64.00. In related news, CEO Steven M. Klosk sold 12,000 shares of the business’s stock in a transaction dated Monday, May 1st. The stock was sold at an average price of $58.20, for a total transaction of $698,400.00. Following the completion of the transaction, the chief executive officer now directly owns 95,328 shares in the company, valued at $5,548,089.60. The transaction was disclosed in a document filed with the SEC, which is available through this link. Over the last 90 days, insiders have sold 36,000 shares of company stock valued at $2,003,640. 2.63% of the stock is owned by company insiders.

About Cambrex Cambrex Corporation (Cambrex) is a life sciences company. It provides products and services for the development and commercialization of generic therapeutics. It operates through four segments, which are manufacturing facilities that have been aggregated as a single segment. Its manufacturing facilities are owned by the subsidiaries, including Cambrex Charles City, Inc, Cambrex Karlskoga AB and Cambrex Profarmaco Milano S.r.l.new TradingView.widget({ “height”: 400, “width”: 625, “symbol”: “CBM”, “interval”: “D”, “timezone”: “Etc/UTC”, “theme”: “White”, “style”: “1”, “locale”: “en”, “toolbar_bg”: “#f1f3f6”, “enable_publishing”: false, “hideideas”: true, “referral_id”: “2588”});

Want to see what other hedge funds are holding CBM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cambrex Co. (NYSE:CBM).

Related posts

Leave a Comment